Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1681/ASN.2010060656 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice.
Front Pharmacol
October 2024
Nephrology and Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Nephrology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Introduction: Diabetic Kidney Disease (DKD) is the main cause of end-stage renal disease in the developed world. The current treatment of the DKD with renin-angiotensin system (RAS) blockade does not totally halt the progression to end stage kidney disease. Currently, several drugs have shown to delay DKD progression such as sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like-1 receptor agonists (GLP-1RA).
View Article and Find Full Text PDFManagement of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis.
BMC Nephrol
June 2024
Fresenius Medical Care, Global Medical Office, Waltham, MA, USA.
Article Synopsis
- This study explores the use of sucroferric oxyhydroxide (SO) for managing high serum phosphorus levels in patients with end-stage kidney disease (ESKD) undergoing peritoneal dialysis (PD).* -
- An analysis of 402 patients showed significant improvements, with the proportion of patients achieving optimal phosphorus levels rising from 32.1% at the start to between 46.5% and 54% over the year, alongside a reduction in the number of phosphate binder pills taken daily.* -
- Overall, SO treatment effectively lowered serum phosphorus levels and decreased pill burden regardless of kidney function changes, suggesting it can be a beneficial option for managing hyperphosphatemia in ESKD patients on PD
Association of long-term aspirin use with kidney disease progression.
Front Med (Lausanne)
December 2023
Division of Nephrology, University of Tennessee Health Science Center, Memphis, TN, United States.
Background: Chronic microinflammation contributes to the progression of chronic kidney disease (CKD). Aspirin (ASA) has been used to treat inflammation for centuries. The effects of long-term low-dose ASA on CKD progression are unclear.
View Article and Find Full Text PDFUrinary single-cell sequence analysis of the urinary macrophage in different outcomes of membranous nephropathy.
Clin Kidney J
December 2023
Department of Nephrology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Background: Great progress has been made in the diagnosis and treatment of membranous nephropathy (MN). However, a significant number of patients do not respond to immunosuppressive therapy and eventually progress to end-stage kidney disease. To investigate the mechanism of different outcome of MN, we performed single-cell sequencing to analyze the urine cells of patients with and without complete remission of MN.
View Article and Find Full Text PDFAssociation of oral iron replacement therapy with kidney failure and mortality in CKD patients.
Clin Kidney J
November 2023
Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Article Synopsis
- Oral iron replacement therapy (IRT) was studied to see its effects on end-stage kidney disease (ESKD) and mortality in patients with chronic kidney disease (CKD) among US veterans.
- The study involved nearly 50,000 patients, revealing that oral IRT did not significantly impact ESKD risk but was linked to a higher overall mortality rate.
- Notably, oral IRT appeared to lower mortality in patients with anemia, suggesting the need for further evaluation of its risks and benefits in individuals without anemia, iron deficiency, or congestive heart failure.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!